Treatment Sequencing Decisions in ALK+ NSCLC

Opinion
Video

This video segment examines therapeutic strategies for managing disease progression on lorlatinib in ALK-positive metastatic NSCLC, including decision-making considerations and scenarios where switching to lorlatinib from another ALK inhibitor may be beneficial.

Video content above is prompted by the following:

  • If this patient were to experience disease progression on lorlatinib, what would be your next therapeutic approach and why?
    • What considerations would guide your decision-making process?
  • If this patient had started on a different ALK inhibitor, when/why might you consider a switch to lorlatinib?
Recent Videos
Future work may focus on determining strategies for protecting the health of patients who undergo surgery during climate disasters.
A study assessed whether physicians would keep patients who received NSCLC surgery in the hospital longer as an improvisational strategy after wildfires.
Related Content
The safety profiles of osimertinib monotherapy and combination therapy were consistent with prior reports in EGFR-mutated non–small cell lung cancer.

Osimertinib Shows Sustained Survival Benefit in EGFR-Mutant NSCLC

Roman Fabbricatore
March 30th 2025
Article

The safety profiles of osimertinib monotherapy and combination therapy were consistent with prior reports in EGFR-mutated non–small cell lung cancer.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Leticia Nogueira, PhD, MPH, highlights how facilities exposed to wildfires tend to have longer lengths of stay for patients undergoing surgery for NSCLC.

Prioritizing Climate Hazard Preparedness Following NSCLC Surgery

Russ Conroy
March 28th 2025
Article

Leticia Nogueira, PhD, MPH, highlights how facilities exposed to wildfires tend to have longer lengths of stay for patients undergoing surgery for NSCLC.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Ensartinib Yields “Promising” Efficacy in Pretrated METex14–positive NSCLC

Ensartinib Yields “Promising” Efficacy in Pretrated METex14–positive NSCLC

Tim Cortese
March 25th 2025
Article

In the phase 2 EMBRACE trial, ensartinib demonstrated an ORR of 53.3%, a DCR of 86.7%, and a tumor shrinkage rate of 33.3% in patients with METex14-positive NSCLC.

Selpercatinib Demonstrates Durable Responses in RET Fusion–Positive NSCLC

Selpercatinib Demonstrates Durable Responses in RET Fusion–Positive NSCLC

Tim Cortese
March 24th 2025
Article

In patients who were pretreated and treatment naïve with RET fusion-positive NSCLC, selpercatinib yielded an ORR of 61.5% and 82.6%, respectively.